Tardive Dyskinesia and Other Movement Disorders Secondary to Aripiprazole
Identifieur interne : 001863 ( Main/Exploration ); précédent : 001862; suivant : 001864Tardive Dyskinesia and Other Movement Disorders Secondary to Aripiprazole
Auteurs : Maria Sierra Pena [États-Unis] ; Toby C. Yaltho [États-Unis] ; Joseph Jankovic [États-Unis]Source :
- Movement disorders [ 0885-3185 ] ; 2011.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
The objective of this report is to draw attention to tardive dyskinesia (TD) caused by aripiprazole, a third generation antipsychotic. TD has been traditionally attributed to typical (first-generation) antipsychotics, but other dopamine receptor blocking drugs and atypical (second- and third-generation) neuroleptics are emerging as an important cause of TD. We reviewed the medical records of patients with TD seen at the Baylor College of Medicine Movement Disorders Clinic between 2002 and 2010 to identify patients with TD associated with aripiprazole. Among 236 patients with TD seen over the specified period, 8 (3.4%) were found to have aripiprazole-associated TD. In 5 patients, TD occurred after exclusive exposure to aripiprazole. The mean age at onset was 55.8 ± 14.8 years with a female predominance. The average duration of treatment with aripiprazole was 18.4 ± 26.4 months. Oro-bucco-lingual stereotypy was seen in all patients. In most patients, TD did not spontaneously improve after stopping aripiprazole. Of the 5 patients treated with tetrabenazine, 4 improved during follow-up. Although aripiprazole, a third generation antipsychotic, has been promoted to have a low risk of TD, the drug accounts for about 3.5% of patients with TD evaluated in a movement disorders clinic. This largest reported series draws attention to the growing incidence of TD and other drug-induced movement disorders associated with "atypical antipsychotics."
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000726
- to stream PascalFrancis, to step Curation: 002592
- to stream PascalFrancis, to step Checkpoint: 000380
- to stream Main, to step Merge: 001970
- to stream Main, to step Curation: 001863
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Tardive Dyskinesia and Other Movement Disorders Secondary to Aripiprazole</title><author><name sortKey="Sierra Pena, Maria" sort="Sierra Pena, Maria" uniqKey="Sierra Pena M" first="Maria" last="Sierra Pena">Maria Sierra Pena</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Yaltho, Toby C" sort="Yaltho, Toby C" uniqKey="Yaltho T" first="Toby C." last="Yaltho">Toby C. Yaltho</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0143237</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 11-0143237 INIST</idno><idno type="RBID">Pascal:11-0143237</idno><idno type="wicri:Area/PascalFrancis/Corpus">000726</idno><idno type="wicri:Area/PascalFrancis/Curation">002592</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000380</idno><idno type="wicri:doubleKey">0885-3185:2011:Sierra Pena M:tardive:dyskinesia:and</idno><idno type="wicri:Area/Main/Merge">001970</idno><idno type="wicri:Area/Main/Curation">001863</idno><idno type="wicri:Area/Main/Exploration">001863</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Tardive Dyskinesia and Other Movement Disorders Secondary to Aripiprazole</title><author><name sortKey="Sierra Pena, Maria" sort="Sierra Pena, Maria" uniqKey="Sierra Pena M" first="Maria" last="Sierra Pena">Maria Sierra Pena</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Yaltho, Toby C" sort="Yaltho, Toby C" uniqKey="Yaltho T" first="Toby C." last="Yaltho">Toby C. Yaltho</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine</s1><s2>Houston, Texas</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Texas</region></placeName><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antipsychotic</term><term>Aripiprazole</term><term>Dyskinesia</term><term>Nervous system diseases</term><term>Neuroleptic</term><term>Tetrabenazine</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term><term>Pathologie du système nerveux</term><term>Aripiprazole</term><term>Antipsychotique</term><term>Neuroleptique</term><term>Tétrabénazine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this report is to draw attention to tardive dyskinesia (TD) caused by aripiprazole, a third generation antipsychotic. TD has been traditionally attributed to typical (first-generation) antipsychotics, but other dopamine receptor blocking drugs and atypical (second- and third-generation) neuroleptics are emerging as an important cause of TD. We reviewed the medical records of patients with TD seen at the Baylor College of Medicine Movement Disorders Clinic between 2002 and 2010 to identify patients with TD associated with aripiprazole. Among 236 patients with TD seen over the specified period, 8 (3.4%) were found to have aripiprazole-associated TD. In 5 patients, TD occurred after exclusive exposure to aripiprazole. The mean age at onset was 55.8 ± 14.8 years with a female predominance. The average duration of treatment with aripiprazole was 18.4 ± 26.4 months. Oro-bucco-lingual stereotypy was seen in all patients. In most patients, TD did not spontaneously improve after stopping aripiprazole. Of the 5 patients treated with tetrabenazine, 4 improved during follow-up. Although aripiprazole, a third generation antipsychotic, has been promoted to have a low risk of TD, the drug accounts for about 3.5% of patients with TD evaluated in a movement disorders clinic. This largest reported series draws attention to the growing incidence of TD and other drug-induced movement disorders associated with "atypical antipsychotics."</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region><settlement><li>Houston</li></settlement><orgName><li>Baylor College of Medicine</li></orgName></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Sierra Pena, Maria" sort="Sierra Pena, Maria" uniqKey="Sierra Pena M" first="Maria" last="Sierra Pena">Maria Sierra Pena</name></region><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><name sortKey="Yaltho, Toby C" sort="Yaltho, Toby C" uniqKey="Yaltho T" first="Toby C." last="Yaltho">Toby C. Yaltho</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001863 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001863 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:11-0143237
|texte= Tardive Dyskinesia and Other Movement Disorders Secondary to Aripiprazole
}}
| This area was generated with Dilib version V0.6.23. |  |